Elevated Cerebrospinal Fluid Total Tau in Niemann‐Pick Disease Type C1 : Correlation With Clinical Severity and Response to Therapeutic Interventions
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Niamh X Cawley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Section on Molecular Dysmorphology, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Developme…. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, tau Proteins, Glycoside Hydrolase Inhibitors, 2-Hydroxypropyl-beta-cyclodextrin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, Together Strong, Ara Parseghian Medical Research Foundation.
Abstract (Originalsprache)
Niemann‐Pick disease, type C1 (NPC1) is an inborn error of intracellular cholesterol transport. Impaired function of NPC1 leads to endolysosomal accumulation of unesterified cholesterol, which results in progressive neurodegeneration. Although the age of onset is variable, classical NPC1 is a pediatric disease. Identification of biomarkers that correlate with clinical phenotype and respond to therapeutic interventions will be essential for developing effective therapeutic interventions. Aβ peptides and Tau protein are primary components of amyloid plaques and neurofibrillary tangles, respectively, which are major pathological features in neurodegenerative disorders. Cerebrospinal fluid (CSF) levels of total Tau, a biomarker of axonal damage, were elevated ~3‐fold ( p < 0.0001) in 106 individuals with Niemann‐Pick disease, type C1, relative to age‐appropriate comparison samples. Baseline CSF total Tau levels correlated with clinical measures of disease severity. Specifically, CSF total Tau levels decreased with increased age of neurological onset ( r s = −0.42, FDR adj. p < 0.0001) and increased with increased Annual Severity Increment Score ( r s = 0.52, FDR adj. p < 0.0001). Baseline CSF total Tau levels were decreased 40% ( p = 0.0066) in individuals being treated with miglustat, and longitudinal analysis substantiated this observation with a 40% decrease ( p < 0.0001, 95% CI 32%–47.4%). Longitudinal analysis also showed a significant ( p = 0.004) decrease of 19% (95% CI 7%–30%) in total Tau levels associated with intrathecal 2‐hydroxypropyl‐β‐cyclodextrin therapy. These data show that CSF total Tau levels are significantly increased in individuals with NPC1, positively correlated with increased disease severity, and respond to therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section on Molecular Dysmorphology, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- Applied and Computational Mathematics and Statistics, University of Notre Dame, Indiana, USA.
- Molecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
- Departments of Pediatrics, Neurological Sciences, and Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.
- Unit on Cellular Stress in Development and Diseases, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland…
- Department of Chemistry and Laboratory of Integrative Neuroscience, University of Illinois Chicago, Chicago, Illinois, USA.
ORCID-Profile: Forbes D Porter
Förderung
- Intramural NIH HHS
- Together Strong
- Ara Parseghian Medical Research Foundation
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Ara Parseghian Medical Research Fund
Zitieren
APA
Cawley, N. X., Zhou, R., Farhat, N. M., Iben, J., Alexander, D. M., Luke, R. A., Padilla, C. J., Mohamed, H. O., Albert, O. K., Robbins, K. P., Rahhal, S., Do, A. D., Berry-Kravis, E., Cologna, S. M., Liu, F., & Porter, F. D. (2025). Elevated Cerebrospinal Fluid Total Tau in Niemann‐Pick Disease Type C1 : Correlation With Clinical Severity and Response to Therapeutic Interventions. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70016
Vancouver
Cawley NX, Zhou R, Farhat NM, Iben J, Alexander DM, Luke RA, et al. Elevated Cerebrospinal Fluid Total Tau in Niemann‐Pick Disease Type C1 : Correlation With Clinical Severity and Response to Therapeutic Interventions. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70016
BibTeX
@article{Cawley2025,
author = {Cawley, Niamh X and Zhou, Ruyu and Farhat, Nicole M and Iben, James and Alexander, Derek M and Luke, Rachel A and Padilla, Cameron J and Mohamed, Hibaaq O and Albert, Orsolya K and Robbins, Kendall P and Rahhal, Samar and Do, An Dang and Berry-Kravis, Elizabeth and Cologna, Stephanie M and Liu, Fang and Porter, Forbes D},
title = {Elevated Cerebrospinal Fluid Total Tau in Niemann‐Pick Disease Type C1 : Correlation With Clinical Severity and Response to Therapeutic Interventions},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.70016}
}
EUVIMED